Innovative nasal spray could delay Alzheimer’s by Over a decade

TEXAS: A groundbreaking study from Texas A&M University suggests that a nasal spray might delay the progression of Alzheimer’s disease by up to 15 years. Researchers tested the spray on a mouse model of early Alzheimer’s and found that it reduced harmful brain inflammation and toxic protein buildup, offering hope for more effective treatments against the disease.
Alzheimer’s, which accounts for 70% of all dementia cases, currently has limited treatment options. While monoclonal antibody drugs like lecanemab and donanemab show promise in removing beta-amyloid plaques linked to the disease, they are expensive and pose risks of significant side effects.
This new nasal spray uses stem cell-derived extracellular vesicles to target overactive brain immune cells—microglia and astrocytes. These cells, while initially protective, can become hyperactive in Alzheimer’s, destroying nerve cells and worsening the disease.In the study, treated mice showed reduced inflammation and fewer beta-amyloid plaques, particularly in the hippocampus, a key region for memory. Behavioral tests also revealed improved cognitive and emotional function compared to untreated mice.
Dr. Steven Allder, a consultant neurologist, emphasized the importance of balancing inflammation reduction with maintaining the brain's natural ability to clear toxic plaques. He praised the study’s findings but warned about potential side effects from altering immune cell behavior, stressing the need for rigorous human trials.
Courtney Kloske, director of scientific engagement at the Alzheimer’s Association, highlighted the significance of diversifying treatment approaches and drug delivery methods like intranasal sprays. “Combination therapies, along with brain-healthy lifestyle guidance, are the future of Alzheimer’s treatment,” she said.
Although promising, experts agree that more research is needed to confirm these findings in humans and evaluate the spray’s long-term safety and effectiveness.